VCP
ZYNE

Verus Capital Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Verus Capital Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$4K Hold
930
– – ﹤0.01% 1246
2019
Q4 		$6K Buy
+930
New +$6.36K ﹤0.01% 1280

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Verus Capital Partners's ZYNE Position: Q1 2020 in Review

Verus Capital Partners held its Zynerba Pharmaceuticals, Inc (ZYNE) position steady in Q1 2020 at 930 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1246.

Verus Capital Partners first reported a position in ZYNE in Q4 2019 and has held it in 2 quarters since. The position peaked at $6K in Q4 2019. 77 funds tracked by Wall St. Rank hold ZYNE as of Q1 2020.

  • Verus Capital Partners held 930 shares of Zynerba Pharmaceuticals, Inc worth $4K as of Q1 2020.
  • Verus Capital Partners left its Zynerba Pharmaceuticals, Inc share count unchanged in Q1 2020.
  • Zynerba Pharmaceuticals, Inc made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #1246 holding.
  • Verus Capital Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's Zynerba Pharmaceuticals, Inc position peaked at $6K in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.